Savient Pharmaceuticals, a US-based a speciality biopharmaceutical company, has named John Johnson chief executive officer; he will also serve as a member of the company's board of directors. He was most recently a senior vice-president at Lilly and president of Lilly Oncology Business Unit. Before that, Mr Johnson was CEO of ImClone Systems.
New CEO appointed at Savient
Savient Pharmaceuticals, a US-based a speciality biopharmaceutical company, has named John Johnson chief executive officer; he will also serve as a member of the company's board of directors. He was most recently a senior vice-president at Lilly and president of Lilly Oncology Business Unit. Before that, Mr Johnson was CEO of ImClone Systems.
More from Business
PAH drug Winrevair generated more than $1bn in sales in its first year on the US market, but the company plans to cut $3bn in costs through 2027 that it will reinvest in additional growth drivers.
PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.
Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.
Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.
More from Scrip
The US FDA approved the complement C3 inhibitor for new indications in C3G and primary IC-MPGN, providing a new growth opportunity for Apellis.
Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.